Chiesa Giulia, Monteggia Elena, Marchesi Marta, Lorenzon Paolo, Laucello Massimo, Lorusso Vito, Di Mario Carlo, Karvouni Evangelia, Newton Roger S, Bisgaier Charles L, Franceschini Guido, Sirtori Cesare R
Department of Pharmacological Sciences, University of Milano, Italy.
Circ Res. 2002 May 17;90(9):974-80. doi: 10.1161/01.res.0000018422.31717.ee.
Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. In previous studies, administration of recombinant AIM-phospholipid (AIM-PL) complexes to hypercholesterolemic rabbits markedly inhibited neointimal formation after arterial injury; moreover, repeated injections of AIM-PL in apoE-deficient mice significantly reduced atherosclerosis progression. The objective of the present study was to determine if a single localized infusion of AIM-PL complexes administered directly to atheromatous lesions could promote plaque regression. Lipid-rich, atheromatous plaques were generated at both common carotid arteries of 25 rabbits by applying a perivascular electric injury, followed by 1.5% cholesterol diet for 90 days. Rabbits were infused with either saline, phospholipid vesicles, or 3 different AIM-PL doses (250, 500, or 1000 mg of protein) delivered through an intravascular ultrasound (IVUS) catheter positioned at the origin of the right carotid. The lesions at the left carotid artery were therefore exposed to the agents systemically. Infusion of AIM-PL at the 2 highest doses caused reduction of right carotid artery plaque area by the end a 90-minute infusion as assessed by IVUS analysis. Plaque area regression was confirmed by histology in carotid arteries receiving direct (500 and 1000 mg doses) and systemic (500 mg dose) delivery, 72 hours after the start of the treatment. Plaque lipid content was associated with significant and similar decreases in Oil Red O staining in both arteries. These results suggest AIM-PL complexes enhanced lipid removal from arteries is the mechanism responsible for the observed plaque changes.
载脂蛋白A-I(米兰)(AIM)是人类载脂蛋白A-I的一种天然变体,能为携带者提供显著的血管疾病防护。在先前的研究中,给高胆固醇血症兔子注射重组AIM-磷脂(AIM-PL)复合物可显著抑制动脉损伤后的内膜增生;此外,在载脂蛋白E缺乏的小鼠中反复注射AIM-PL可显著减缓动脉粥样硬化进程。本研究的目的是确定将AIM-PL复合物直接局部注入动脉粥样硬化病变部位是否能促进斑块消退。通过对25只兔子的双侧颈总动脉施加血管周围电损伤,随后给予1.5%胆固醇饮食90天,从而在其双侧颈总动脉形成富含脂质的动脉粥样硬化斑块。通过置于右颈动脉起始处的血管内超声(IVUS)导管,给兔子输注生理盐水、磷脂囊泡或3种不同剂量的AIM-PL(250、500或1000毫克蛋白质)。因此,左颈动脉的病变会全身性接触这些药物。IVUS分析评估显示,输注2种最高剂量的AIM-PL在90分钟输注结束时可使右颈动脉斑块面积减小。在治疗开始72小时后,组织学检查证实接受直接(500和1000毫克剂量)和全身性(500毫克剂量)给药的颈动脉斑块面积缩小。两条动脉中斑块脂质含量均显著下降,且油红O染色结果相似。这些结果表明,AIM-PL复合物增强从动脉中清除脂质是观察到的斑块变化的作用机制。